Shanghai Henlius Biotech Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Shanghai Henlius Biotech ha un patrimonio netto totale di CN¥2.6B e un debito totale di CN¥3.8B, che porta il suo rapporto debito/patrimonio netto a 147%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥10.0B e CN¥7.4B. L'EBIT di Shanghai Henlius Biotech è CN¥796.2M rendendo il suo rapporto di copertura degli interessi 7.7. Ha liquidità e investimenti a breve termine pari a CN¥665.5M.

Informazioni chiave

147.0%

Rapporto debito/patrimonio netto

CN¥3.79b

Debito

Indice di copertura degli interessi	7.7x
Contanti	CN¥665.50m
Patrimonio netto	CN¥2.58b
Totale passività	CN¥7.40b
Totale attività	CN¥9.98b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { 2696 di CN¥2.4B ) non coprono le sue passività a breve termine ( CN¥4.9B ).

Passività a lungo termine: Le attività a breve termine di 2696 ( CN¥2.4B ) non coprono le sue passività a lungo termine ( CN¥2.5B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 121.2% ) di 2696 è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di 2696 è aumentato da 40.2% a 147% negli ultimi 5 anni.

Copertura del debito: Il debito di 2696 è ben coperto dal flusso di cassa operativo ( 25.5% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 2696 sono ben coperti dall'EBIT ( 7.7 x copertura).

Bilancio

Scoprire le aziende sane

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/21 12:16
Prezzo dell'azione a fine giornata	2024/12/20 00:00
Guadagni	2024/06/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Shanghai Henlius Biotech, Inc. è coperta da 15 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Yang Huang	BofA Global Research
Wangbin Zhou	Citigroup Inc
Eva Zhao	Citigroup Inc

Shanghai Henlius Biotech Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

Recent updates

New major risk - Revenue and earnings growth

Shanghai Henlius Biotech Announces Application for the Phase 1b/2 Clinical Trial of HLX43 for Injection Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces New Drug Application for New Indication of Hansizhuang (Serplulimab Injection)

Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in an International Multi-Center Phase 3 Clinical Study of HLX22

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Shanghai Henlius Biotech, Inc. Announces First Patient in Japan Dosed in an International Multicentre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) in Combination with Bevacizumab Injection and Chemotherapy for the First-Line Treatment of Metastatic Colorectal Cancer (mCRC)

Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

Shanghai Henlius Biotech, Inc. Receives Positive Opinion from the Committee Formedicinal Products for Human Use (Chmp)Of the European Medicines Agency (Ema)

Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of Pembrolizumab Biosimilar HLX17 (Recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection)

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

Shanghai Henlius Biotech, Inc. Announces Company Secretary Changes

Shanghai Henlius Biotech, Inc. to Report First Half, 2024 Results on Aug 26, 2024

Shanghai Henlius Biotech, Inc. Announces the First Patient Dose in A Phase 2 Clinical Trial of HLX53

Shanghai Henlius Biotech, Inc. Announces International Multicentre Phase 3 Clinical Trial for the First-Line Treatment of Metastatic Colorectal Cancer in Japan

Shanghai Henlius Biotech, Inc. Announces Chief Financial Officer Changes

Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) agreed to acquire 78.3% stake in Shanghai Henlius Biotech, Inc. (SEHK:2696) from a group of shareholders for CNY 4.3 billion.

Investor sentiment improves as stock rises 19%

Less than half of directors are independent

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications

Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration (FDA)

Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration

New major risk - Financial position

Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Shanghai Henlius Biotech, Inc. Receives Approval from United States Food and Drug Administration for Application for Phase 1 Clinical Trial of HLX42 for Injection (Antibody-Drug Conjugate Targeting EGFR with Novel DNA Topoisomerase I Inhibitor)

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13

New minor risk - Financial position

Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023

Shanghai Henlius Biotech, Inc. Announces Shenzhen Nansiuzhuiang in Combination with Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Shanghai Henlius Biotech, Inc. Announces NMPA Approvals of Two ADC Candidates for IND

Shanghai Henlius Biotech, Inc. Announces the First Patient in Europe Has Been Dosed in the International Multi-Centre Phase 3 Clinical Trial

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication of Hansizhuang (Serplulimab Injection) an Innovative Anti-PD-1 Monoclonal Antibody

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.47 loss in 1H 2022)

Shanghai Henlius Biotech, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Consensus EPS estimates fall by 31%

Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Phase 2 Clinical Trial of HLX26

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

Shanghai Henlius Biotech, Inc. Announces Application for Phase 2 Clinical Trial of Hlx26

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Consensus revenue estimates increase by 13%

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces United States Food and Drug Administration Accepts the Biologic License Application for HLX02

Shanghai Henlius Biotech, Inc. Announces the First Patient in USA Has Been Dosed in Aninternational Multicentre Phase 3 Clinical Study Ofrecombinant Anti-Vegf Humanised Monoclonalantibody Ophthalmic Injection Hlx04-Ofor the Treatment of Wet Age-Related Maculardegeneration (Wamd)